Date: 2017-09-27
Type of
information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the European Association for Vision and Eye Research (EVER) 20th Annual Meeting
Company: Thrombogenics (Belgium)
Product: THR-687
Action
mechanism:
Disease:
Therapeutic
area:
Country:
Trial
details:
Latest
news:
- • On September 27, 2017, ThromboGenics announced that THR-687 pre-clinical data will be presented at the European Association for Vision and Eye Research (EVER) 20th Annual Meeting, which is being held in Nice, France, from September 27-30th. The poster presentation 'THR-687, a potent small molecule integrin receptor antagonist, holds promise as a therapeutic approach for back-of-the-eye vascular pathologies' provides further pre-clinical evidence supporting the development of THR-687. The study evaluated the integrin-blocking capacity and anti-angiogenic properties of THR-687, a novel small molecule pan RGD integrin antagonist, under development to treat a broad range of patients with diabetic retinopathy (DR), with or without diabetic macular edema (DME).
- Dr. Patrik De Haes, MD, CEO of ThromboGenics NV said, "We are pleased to have this opportunity to present these pre-clinical data on THR-687 at the EVER meeting. THR-687 is one of 4 novel compounds we are developing for treatment of diabetic eye disease. The encouraging preclinical data we are presenting highlight our progress with THR-687 which is on track to enter the clinic in H1 2018."
Is
general: Yes
